TY - JOUR
T1 - Day and Night Closed-Loop Control in Adults With Type 1 Diabetes A comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management
AU - Luijf, Yoeri M.
AU - DeVries, J. Hans
AU - Zwinderman, Koos
AU - Leelarathna, Lalantha
AU - Nodale, Marianna
AU - Caldwell, Karen
AU - Kumareswaran, Kavita
AU - Elleri, Daniela
AU - Allen, Janet M.
AU - Wilinska, Malgorzata E.
AU - Evans, Mark L.
AU - Hovorka, Roman
AU - Doll, Werner
AU - Ellmerer, Martin
AU - Mader, Julia K.
AU - Renard, Eric
AU - Place, Jerome
AU - Farret, Anne
AU - Cobelli, Claudio
AU - del Favero, Simone
AU - Dalla Man, Chiara
AU - Avogaro, Angelo
AU - Bruttomesso, Daniela
AU - Filippi, Alessio
AU - Scotton, Rachele
AU - Magni, Lalo
AU - Lanzola, Giordano
AU - Di Palma, Federico
AU - Soru, Paola
AU - Toffanin, Chiara
AU - de Nicolao, Giuseppe
AU - Arnolds, Sabine
AU - Benesch, Carsten
AU - Heinemann, Lutz
PY - 2013
Y1 - 2013
N2 - OBJECTIVETo compare two validated closed-loop (CL) algorithms versus patient self-control with CSII in terms of glycemic control.RESEARCH DESIGN AND METHODSThis study was a multicenter, randomized, three-way crossover, open-label trial in 48 patients with type 1 diabetes mellitus for at least 6 months, treated with continuous subcutaneous insulin infusion. Blood glucose was controlled for 23 h by the algorithm of the Universities of Pavia and Padova with a Safety Supervision Module developed at the Universities of Virginia and California at Santa Barbara (international artificial pancreas [iAP]), by the algorithm of University of Cambridge (CAM), or by patients themselves in open loop (OL) during three hospital admissions including meals and exercise. The main analysis was on an intention-to-treat basis. Main outcome measures included time spent in target (glucose levels between 3.9 and 8.0 mmol/L or between 3.9 and 10.0 mmol/L after meals).RESULTSTime spent in the target range was similar in CL and OL: 62.6% for OL, 59.2% for iAP, and 58.3% for CAM. While mean glucose level was significantly lower in OL (7.19, 8.15, and 8.26 mmol/L, respectively) (overall P = 0.001), percentage of time spent in hypoglycemia ( <3.9 mmol/L) was almost threefold reduced during CL (6.4%, 2.1%, and 2.0%) (overall P = 0.001) with less time 2.8 mmol/L (overall P = 0.038). There were no significant differences in outcomes between algorithms.CONCLUSIONSBoth CAM and iAP algorithms provide safe glycemic control
AB - OBJECTIVETo compare two validated closed-loop (CL) algorithms versus patient self-control with CSII in terms of glycemic control.RESEARCH DESIGN AND METHODSThis study was a multicenter, randomized, three-way crossover, open-label trial in 48 patients with type 1 diabetes mellitus for at least 6 months, treated with continuous subcutaneous insulin infusion. Blood glucose was controlled for 23 h by the algorithm of the Universities of Pavia and Padova with a Safety Supervision Module developed at the Universities of Virginia and California at Santa Barbara (international artificial pancreas [iAP]), by the algorithm of University of Cambridge (CAM), or by patients themselves in open loop (OL) during three hospital admissions including meals and exercise. The main analysis was on an intention-to-treat basis. Main outcome measures included time spent in target (glucose levels between 3.9 and 8.0 mmol/L or between 3.9 and 10.0 mmol/L after meals).RESULTSTime spent in the target range was similar in CL and OL: 62.6% for OL, 59.2% for iAP, and 58.3% for CAM. While mean glucose level was significantly lower in OL (7.19, 8.15, and 8.26 mmol/L, respectively) (overall P = 0.001), percentage of time spent in hypoglycemia ( <3.9 mmol/L) was almost threefold reduced during CL (6.4%, 2.1%, and 2.0%) (overall P = 0.001) with less time 2.8 mmol/L (overall P = 0.038). There were no significant differences in outcomes between algorithms.CONCLUSIONSBoth CAM and iAP algorithms provide safe glycemic control
U2 - https://doi.org/10.2337/dc12-1956
DO - https://doi.org/10.2337/dc12-1956
M3 - Article
C2 - 24170747
SN - 0149-5992
VL - 36
SP - 3882
EP - 3887
JO - Diabetes Care
JF - Diabetes Care
IS - 12
ER -